Starling Oncology Narrows Losses, But the Beat Didnt Save the Stock

Starling Oncology (STLN) reported fiscal 2026 Q2 earnings on Aug 07th, 2026. The results demonstrated a significant improvement in profitability metrics, with the company narrowing its net loss substantially compared to the prior year period.

Revenue

The total revenue of Starling Oncology increased by 34.6% to $161.28 million in 2026 Q2, up from $119.80 million in 2025 Q2. Patient services contributed $58.83 million, while the specialty pharmacy segment generated $98.61 million. Additionally, clinical trials and other services accounted for $3.85 million, bringing the total operating revenue to $161.28 million.

Earnings/Net Income

Starling Oncology narrowed losses to $0.08 per share in 2026 Q2 from a loss of $0.15 per share in 2025 Q2 (46.7% improvement). Meanwhile, the company successfully narrowed its net loss to $-9.79 million in 2026 Q2, reducing losses by 42.4% compared to the $-17.01 million net loss reported in 2025 Q2. The EPS performance indicates a positive trajectory toward profitability, reflecting improved operational efficiency.

Price Action

The stock price of Starling Oncology has edged down 1.84% during the latest trading day.

Post-Earnings Price Action Review

Backtest conclusion: the “buy STLN after a revenue beat, hold 30 days” setup has not shown a reliable edge in the latest available data. STLN’s most recent earnings release was August 6, 2026, and the 30-day holding-period return from the earnings close to the close 30 trading days later was -13.7%. STLN’s closing price was $6.41 on August 6, 2026 and $5.43 on August 7, 2026 after a 30-trading-day hold.

The broader market screening for recent earnings events with positive YoY revenue growth shows a cluster of releases around mid-to-late July 2026, including major names like Eli Lilly, Caterpillar, and Berkshire Hathaway. This context suggests that while revenue growth is a common positive signal, STLN’s subsequent price decline indicates the market may have already priced in the beat, focused more on guidance or balance-sheet risks, or viewed the beat as a one-day event rather than a sustained catalyst. Consequently, the setup is not automatically profitable for STLN, highlighting the need for additional filters like guidance or margins in future strategy prototypes.

CEO Commentary

Daniel Virnich, CEO of Starling Oncology, characterized the second quarter of 2026 as a milestone, highlighting a 35% year-over-year revenue increase and the first positive Adjusted EBITDA. He attributed growth to expanded capitated contracts, including new delegated arrangements in Nevada and Oregon, and a California exclusivity agreement adding 230,000 lives. Virnich emphasized that the upcoming launch of the Starling Nexus provider portal will deepen engagement and adherence to clinical pathways. Expressing confidence in the company's trajectory, he noted that these operational achievements support the path to sustained positive Adjusted EBITDA, prompting an upward revision of the full-year financial outlook.

Guidance

Starling Oncology updated its full-year 2026 guidance, raising revenue expectations to $650–$670 million from the previous $630–$650 million range. Gross profit guidance was increased to $105–$110 million, while Adjusted EBITDA guidance was revised to $2–$7 million from $0–$9 million. Free Cash Flow guidance remains unchanged at $5–$15 million. For the third quarter of 2026, the company anticipates Adjusted EBITDA of $500 thousand to $1.5 million, driven by the ramp-up of Florida delegated lives. Management expects approximately $150 million in capitated revenue for the full year, with a Medical Loss Ratio projected between 80% and 90% over the next twelve months.

Additional News

Starling Oncology completed a strategic refinancing in July, repaying its $86 million senior secured convertible note through a $75 million term loan and approximately $11 million in cash. This move extends debt maturities from 2027 to 2031 without raising additional equity or diluting shareholders. Additionally, the company announced a rebranding to Starling Oncology to better reflect its scope as a national value-based oncology leader. Management also highlighted the addition of 310,000 capitated lives through new contracts in Nevada and Oregon, along with an exclusivity agreement in California. These operational expansions are expected to drive approximately $50 million in annualized capitated revenue, reinforcing the company's growth trajectory in value-based care models.